Literature DB >> 7224738

Gram-negative bacteremias. Analysis of factors for clinical assessment of gentamicin resistance.

J M Lynch, G R Hodges, G M Clark, D L Dworzack.   

Abstract

We reviewed the charts of 163 patients with 183 episodes of Gram-negative bacillary bacteremia to determine a clinical profile that would select patients at high risk for experiencing gentamicin-sulfate-resistant Gram-negative bacillary bacteremia at our hospital. Gentamicin-resistant Gram-negative bacilli were only associated with institution-acquired bacteremia. Among institution-acquired episodes, urinary tract infection, diagnostic or therapeutic procedures of the lower respiratory tract or urinary tract, presence of pneumonic infiltrate on chest roentgenogram, prior therapy with gentamicin, and prior therapy with other antibiotics were significant risk factors. Because only two of the 29 gentamicin-resistant bacteria that were tested against amikacin base were resistant to amikacin, we advocate initial treatment with amikacin for patients with evidence of an institution-acquired Gram-negative bacteremic episode. Gentamicin is still our initial choice for a community-acquired episode.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7224738     DOI: 10.1001/archinte.141.5.582

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  3 in total

1.  Antimicrobial susceptibility in gram-negative bacteremia: are nosocomial isolates really more resistant?

Authors:  J E McGowan; E C Hall; P L Parrott
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

2.  Bacteremia in adult men.

Authors:  D J Flournoy; L Adkins; R D McCaffree
Journal:  J Natl Med Assoc       Date:  1987-08       Impact factor: 1.798

3.  Superior activity of N-formimidoyl thienamycin against gentamicin-resistant Pseudomonas aeruginosa.

Authors:  P R Michael; R H Alford; Z A McGee
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.